Smart Share Global Ltd (EM) Stock News

Shareholder class action lawsuits have been filed against Embecta Corp. and Via Transportation Inc., with allegations of false statements and failure to disclose segment weakness and revenue guidance disruptions. Additionally, Holzer & Holzer, LLC announced an investigation into ADTRAN Holdings Inc. regarding potential federal securities law violations. Investors who suffered losses during the relevant periods are encouraged to contact the law firm.

Following the announcement of its proposed merger with WDP, Standard & Poor's has placed ARGAN's BBB- credit rating on CreditWatch with positive outlook, signaling a potential upgrade of at least one notch. S&P cited the merger's expected benefits including increased size, strengthened rental income profile, expanded geographic diversification, and reduced client concentration risk, positioning the combined entity as a European logistics real estate leader.

Embecta Corp. faces a securities fraud class action lawsuit after its stock plummeted 57.8% on May 5, 2026, when the company revealed disappointing Q2 results and admitted to significant market softness in insulin pens and pen needles. Investors allege the company misrepresented the strength of its insulin pen portfolio prior to the announcement. The lead plaintiff deadline is August 17, 2026.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased shares between August 9, 2024 and March 25, 2026 can join the lawsuit with a deadline of August 10, 2026.

Rosen Law Firm is reminding investors who purchased Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Embecta Corp., where investors who purchased stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The lawsuit alleges that Embecta made false statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. The lead plaintiff deadline is August 17, 2026. Similar class actions are also mentioned for Calix, Inc. and Lucid Group, Inc.

Soitec reports on its liquidity contract managed by BNP Paribas for the first half of 2026. During H1 2026, 227,346 shares were purchased for €17.36 million and 288,875 shares were sold for €23.29 million across 4,546 transactions. The liquidity account held 24,442 shares and €6.36 million as of June 30, 2026.

A class action lawsuit has been filed against Zillow Group, Inc. for allegedly making false and misleading statements regarding its agreement with Redfin Corporation. The lawsuit claims Zillow mischaracterized the Redfin deal as a partnership rather than an acquisition, failed to disclose heightened regulatory and antitrust risks, and downplayed legal exposure. Investors who purchased Zillow stock between February 11, 2025 and May 7, 2026 have until August 10, 2026 to apply as lead plaintiff.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. Embecta slashed its full-year EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

ARCpoint Inc. (TSXV: ARC), a healthcare technology company, announced it will miss its July 29, 2026 filing deadline for annual financial statements due to lack of available funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and expects to file by September 29, 2026. During the MCTO period, insiders will be restricted from trading shares, though public trading will continue.

Brancous LP1, a shareholder of Braemar Hotels & Resorts, criticizes the Board for wasting company resources attacking shareholders instead of negotiating a lower Ashford termination payment. The shareholder claims the Board is pursuing a 'stealth liquidation' through asset sales to trigger a $480 million Change of Control payment to Ashford, which Brancous estimates at $7.00 per share. Brancous demands the Board declare a special dividend of at least $1.00 per share, renegotiate the Ashford payment, and allow shareholders to elect an independent Board.

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp., Nano-X Imaging Ltd., and Lucid Group, Inc. during specified periods to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding financial guidance and business performance. Investors with losses exceeding $100,000 are encouraged to secure counsel before the August 17, 2026 lead plaintiff deadline.

Embecta Corp. faces a securities fraud class action lawsuit after revealing a 14% revenue decline due to weakness in pen needle sales and lowering fiscal 2026 guidance on May 5, 2026. The stock plummeted 57.8% to $3.90 per share. Defendants are accused of making materially false statements and failing to disclose material adverse facts about the company's business and prospects during the Class Period (November 25, 2025 - May 4, 2026). The deadline to file a lead plaintiff motion is August 17, 2026.

A securities class action lawsuit has been filed against Insulet Corporation alleging the company made false and misleading statements about its manufacturing controls and procedures. The lawsuit covers investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. Two voluntary medical device corrections were disclosed in March and May 2026 involving manufacturing issues with Omnipod products, resulting in significant stock price declines. The deadline to seek lead plaintiff status is August 31, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed full-year EPS guidance by 43% and cut its dividend by 93%, prompting investigations into whether management knew about revenue headwinds but failed to disclose them.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Embecta Corp., First Solar Inc., ZoomInfo Technologies Inc., and Peabody Energy Corporation. The lawsuits allege that defendants made false or misleading statements regarding business guidance, operational performance, and market conditions. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

Berger Montague has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL failed to disclose that the NHS-Galleri trial was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. On February 19, 2026, GRAIL announced the trial's primary endpoint had not been met, causing the stock to plummet approximately 50.55% in a single trading day from $101.53 to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) after its stock plummeted 57.8% on May 5, 2026. The company allegedly misled investors about the strength of its insulin pen needle product portfolio, claiming resilience while facing significant competition and market softness. The disappointing Q2 2026 results revealed share loss in the pen needle category and led to a dividend reduction from $0.15 to $0.01 per share.

A federal securities class action has been filed against Via Transportation (NYSE:VIA) alleging that its September 2025 IPO offering documents were false and misleading. The lawsuit claims the company omitted material information about declining Platform Annual Run-Rate Revenue (ARR) and growth obstacles in Germany. Since the IPO at $46/share, the stock has declined significantly following multiple earnings announcements revealing operational challenges. Investors must apply by August 10, 2026 to become lead plaintiff.

Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.

Rosen Law Firm announces a securities class action lawsuit against Embecta Corp., alleging the company made false and misleading statements about its fiscal results and pen needle business guidance. Investors who purchased EMBC stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed its 2026 EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

Amerant Investments announced the appointment of Ricardo Sucre as Head of International Wealth Management Business Development. Sucre brings over 20 years of experience from leading financial institutions including Morgan Stanley and Bolton Global Capital. The appointment reflects Amerant's strategic focus on expanding its international wealth management platform and attracting experienced financial advisors to its integrated banking and investment services model.

VXUS and IEMG represent two distinct approaches to international investing. VXUS offers broader diversification across 8,738 holdings with a lower 0.05% expense ratio and steadier returns, while IEMG focuses on emerging markets with higher growth potential but greater volatility. IEMG outperformed over 1 and 3 years (35.7% and 22.6% annualized returns), but VXUS won over 5 and 10-year periods. The choice depends on investor preference for geographic exposure and risk tolerance.

Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its pen needle business and financial guidance. On May 5, 2026, Embecta disclosed a revenue decline of over 14% versus guided flat to 2% decline, causing the stock to plummet 57.8% in a single day. Investors who purchased Embecta securities between November 25, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with the lead plaintiff deadline set for August 17, 2026.

The article compares two energy infrastructure ETFs: Global X MLPX offers lower costs (0.45% expense ratio), higher dividend yield (4.10%), and better 1-year returns (23.20%), but with higher volatility and less diversification (29 holdings). First Trust EMLP provides broader diversification (65 holdings), lower volatility, and an ESG screen, but charges a higher expense ratio (0.95%) and offers lower dividend yield (2.80%). The choice depends on investor risk tolerance and income preferences.

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp. (EMBC), Zillow Group (ZG), and Barclays PLC (BCS) during specified periods to join securities class action lawsuits. The firm alleges that Embecta made false statements about its fiscal results and pen needle business guidance before missing expectations and cutting guidance. The lead plaintiff deadline for Embecta is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly misleading investors about the stability of its pen needle business. The company provided optimistic guidance in February 2026 but reported a 61% sequential EPS decline in Q2 2026, slashed full-year guidance by 43%, and cut its dividend by 93%, triggering a significant stock selloff. Investors are urged to report losses by August 17, 2026.

Class action lawsuits have been filed against Embecta Corp., Black Rock Coffee Bar, Inc., and First Solar, Inc. for allegedly making materially false statements and failing to disclose material adverse facts. Embecta faces allegations of misleading guidance and U.S. pen needle market weakness. Black Rock Coffee is accused of overstating expansion strategy and experiencing sales cannibalization. First Solar is alleged to have overstated its ability to manage U.S. tariff impacts. Lead plaintiff deadlines range from August 17-24, 2026.